

#### Vaccines and Global Health: The Week in Review 21 October 2023 :: Issue 723 Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at <u>https://centerforvaccineethicsandpolicy.net</u>. This blog allows full text searching of over 27,000 entries. Comments and suggestions should be directed to David R. Curry, MS Editor and Executive Director Center for Vaccine Ethics & Policy david.r.curry@centerforvaccineethicsandpolicy.org

**Request email delivery of the pdf:** If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to <u>david.r.curry@centerforvaccineethicsandpolicy.org</u>.

**Support this knowledge-sharing service:** Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click <u>here</u> to donate and thank you in advance for your contribution.

#### Contents [click to move among sections]

- :: <u>Milestones, Perspectives</u>
- :: <u>WHO</u>
- :: Organization Announcements
- :: Journal Watch
- :: <u>Pre-Print Servers</u>
- :: <u>Think Tanks</u>

# Milestones, Perspectives

.....

#### Joint Statement on Action plan to drive equitable expansion of immunisation in Africa

Geneva, 16 October 2023

The African Union Commission (AUC), Africa Centres for Disease Control and Prevention (Africa CDC) and Gavi, the Vaccine Alliance last week concluded a three-day forum to outline a pathway towards extensive collaboration in alignment of the tripartite <u>Memorandum of</u> <u>Understanding</u> signed between the organizations in May 2023.

Through the MoU, the three organizations commit to increase access and accelerate the uptake of life-saving vaccines across African Union member states, by leveraging their collective resources, expertise and expansive networks to collaboratively address a broad range of health issues.

Senior leadership from all three organisations as well as technical experts, contributed to the actionoriented sessions, which were aligned across the following **cross-cutting issues:** 

- Fostering sustainable and equitable systems for immunisation, including reaching zero dose children, overcome barriers, and building a resilient health workforce
- Building public trust and confidence in immunization, including demand generation and social behavioral change, and aligning immunization-related communications and advocacy
- Realizing the continental vision to expand vaccine manufacturing in Africa, including the facilitation of efficient regulatory pathways and timely authorisations of vaccines and efficient, effective pharmacovigilance
- Strengthening diagnostic and disease surveillance capacity for epidemic prone vaccinepreventable diseases

In addition to these discussions, the delegations also engaged in preliminary discussions on the design of Gavi's next five-year strategic period, "Gavi 6.0", which will run from 2026-2030, as well as ways to align on pandemic prevention, preparedness and response activities.

The AUC and Africa CDC delegation was led by Dr Ahmed Ogwell Ouma, Ag. Deputy Director General, Africa CDC. Gavi's delegation was led by Pascal Barollier, Chief Engagement Officer and Thabani Maphosa, Managing Director, Country Programmes Delivery.

"We have come together to give life to the tripartite MoU and secure the health of the continent of Africa. We have committed to work in synergy and give Africa tangible results for immunisation in the shortest time," said Dr Ahmed Ogwell Ouma, Deputy Director General of the Africa CDC.

"The work our organizations undertake is intrinsically linked, and it is critical that we have come together in service of the AUC's continental vision for public health, the New Public Health Order," said Thabani Maphosa, Managing Director of Country Programmes Delivery at Gavi. "This week's workshop was the time to turn our deep commitment to collaboration into a tangible plan of action. Gavi is proud to be a partner to the African Union Commission and Africa CDC, and we are excited to be expanding this partnership into so many aspects of our work."

	1		
	1		

# Featured Journal Content

# Global regulatory reforms to promote equitable vaccine access in the next pandemic

*Review* Richard Mahoney, Peter J. Hotez, Maria Elena Bottazzi **PLoS Global Public Health** | published 18 Oct 2023 https://doi.org/10.1371/journal.pgph.0002482

#### Abstract

There is broad consensus that the global response to the Covid-19 pandemic was inadequate, leading to unacceptable levels of avoidable morbidity and mortality. Three strategic missteps led to the lack of equitable vaccine access: The heavy reliance on commercial vaccine manufacturers in high-income countries (HICs) versus low- and middle-income countries (LMICs); the emergence of vaccine nationalism restricting and delaying the supply of vaccines to LMICs; and an inadequate support or recognition for LMIC national regulatory authorities. To avoid these inequities in a future pandemic, we focus on three successful vaccine development and technology transfer case studiesthe Hepatitis B vaccine produced in South Korea in the 1980s; the Meningitis A vaccine for Africa led by Program for Appropriate Technologies in Health (PATH) and the World Health Organization (WHO) in the 2000s; and a recombinant SARS CoV-2 protein-based vaccine technology from the Texas Children's Hospital transferred to India and to Indonesia. In addition to expanding support for academic or non-profit product development partnerships, our analysis finds that an essential step is the strengthening of selected LMIC regulatory systems to become Stringent Regulatory Authorities (SRAs), together with a re-prioritization of the WHO Pregualification (PQ) system to ensure early vaccine availability in LMICs especially during pandemics. Advancing LMIC National Regulatory Authorities (NRAs) to Stringent Regulatory Authorities (SRAs) status will require substantial resources, but the benefits for future pandemic control and for health in LMIC would be immense. We call on the WHO, United Nation (UN) agencies and SRAs, to collaborate and implement a comprehensive roadmap to support LMIC regulators to achieve stringent status by 2030.

#### ...Conclusions

The vaccine development strategy of the COVID-19 pandemic in which vast resources were allocated mostly to HIC producers to take over and finalize the development of vaccines that had initially been developed largely in academia and government was a failure in terms of meeting the needs of people in LMICs. Vaccine nationalism and the inertia of the global health enterprise greatly impeded LMIC access to needed vaccines. Therefore, a major overhaul of the global pandemic response ecosystem such as proposed by Torreele [10] will be necessary.

Ensuring that people in LMICs can receive vaccines rapidly after the outbreak of a pandemic will depend in large part on the availability of vaccine producers in LMICs. The greatest barrier to LMIC producers being able to supply other LMICs is the necessity to meet regulatory requirements and, especially, to obtain WHO PQ. The highest priority should be capacity building and strengthening support to selected LMIC NRAs to help them become SRAs. In the meantime, additional assistance should be provided to LMIC manufacturers so they can expeditiously obtain PQ. WHO has recognized this need and is prepared to provide technical assistance to LMIC manufacturers [48]. However, this program has limited funding.

A second barrier is the lack of recognition for academic-based and non-profit product development partnerships as innovators that can work hand-in-glove with LMIC vaccine producers. The three examples here provide essential case studies.

Pandemic vaccine development considerations could be seen as the justification for a broad program to enhance LMIC NRAs to SRAs [49]. Implementing such a program would be a necessary step for

LMICs to achieve greater self-sufficiency in developing, approving, supplying and monitoring needed vaccines, drugs and devices for their populations and especially for the diseases that are important in their countries. In turn, to maintain SRA status within an LMIC, would require considerable resources and time and should be seen as necessary for improving health in LMICs in addition to ensuring a more effective response to future pandemics [50].

Furthermore, the existence of SRAs in vaccine producing LMICs and, in the meantime, of a robust rapidly acting WHO PQ system that gives priority to LMIC producers will facilitate and encourage vaccine developers, especially those in academia or the non-profit world, to prioritize the transfer of their vaccine to LMIC producers.

Our recommendations address one of the major issues that impeded an effective response to the COVID-19 pandemic, the urgency to strengthen regulatory systems in LMICs to become SRAs, together with a re-prioritization of the WHO Prequalification (PQ) system to ensure rapid actions for LMICs especially during pandemics. To address these hurdles, we call on the WHO, UN agencies and SRAs, to collaborate and implement a comprehensive roadmap to support LMIC regulators, including the AMA, to achieve stringent status by 2030. The designation of LMIC-based SRAs will empower local vaccine innovations and facilitate vaccine development with regionally appropriate frameworks leading to accessible vaccines.

:::::: :::::::

#### **Regulatory considerations on artificial intelligence for health**

WHO 2023 :: 61 pages ISBN: 9789240078871 (electronic version) 9789240078888 (print version) PDF: <u>9789240078871-eng.pdf (753.8Kb)</u>

...This publication, which is based on the work of the WG-RC, aims to deliver an overview of regulatory considerations on AI for health that covers the following six general topic areas: documentation and transparency, the total product lifecycle approach and risk management, intended use and analytical and clinical validation, data quality, privacy and data protection, and engagement and collaboration. This overview is not intended as guidance or as a regulatory framework or policy. Rather, it is a discussion of key regulatory considerations and a resource that can be considered by all relevant stakeholders – including developers who are exploring and developing AI systems, regulators and policy-makers who in the process of identifying approaches to manage and facilitate AI systems, manufacturers who design and develop AI-enabled medical devices, and health practitioners who deploy and use such medical devices and AI systems.

Consequently, the WG-RC recommends that stakeholders take into account the following considerations as they continue to develop frameworks and best practices for the use of AI in health care and therapeutic development:

**1. Documentation and transparency:** Pre-specifying and documenting the intended medical purpose and development process – such as the selection and use of datasets, reference standards, parameters, metrics, deviations from original plans and updates during the phases of development – should be considered in a manner that allows for the tracing of the development steps as appropriate. A risk-based approach should be considered also for the level of documentation and record-keeping utilized for the development and validation of AI systems.

**2. Risk management and AI systems development lifecycle approaches:** A total product lifecycle approach should be considered throughout all phases in the life of an AI system, namely: pre-market development management, post-market surveillance and change management. In

addition, it is essential to consider a risk management approach that addresses risks associated with AI systems, such as cybersecurity threats and vulnerabilities, underfitting, algorithmic bias etc.

3. Intended use, and analytical and clinical validation: Initially, providing transparent documentation of the intended use of the AI system should be considered. Details of the training dataset composition underpinning an AI system – including size, setting and population, input and output data and demographic composition – should be transparently documented and provided to users. In addition, it is key to consider demonstrating performance beyond the training and testing data through external analytical validation in an independent dataset. This external validation dataset should be representative of the population and setting in which it is intended to deploy the AI system and should be independent of the dataset used for developing the AI model during training and testing. Transparent documentation of the external dataset and performance metrics should be provided. Furthermore, it is important to consider a graded set of requirements for clinical validation based on risk. Randomized clinical trials are the gold standard for evaluation of comparative clinical performance and could be appropriate for the highest-risk tools or where the highest standard of evidence is required. In other situations, prospective validation can be considered in a real-world deployment and implementation trial which includes a relevant comparator that uses accepted groups. Finally, a period of more intense post-deployment monitoring should be considered through post-market surveillance and market surveillance for AI systems.

**4. Data quality:** Developers should consider whether available data are of sufficient quality to support the development of the AI system to achieve the intended purpose. Furthermore, developers should consider deploying rigorous pre-release evaluations for AI systems to ensure that they will not amplify any of the issues discussed in Section 5.4 of this document, such as biases and errors. Careful design or prompt troubleshooting can help identify data quality issues early and can prevent or mitigate possible resulting harm. Stakeholders should also consider mitigating data quality issues and the associated risks that arise in health-care data, as well as continue to work to create data ecosystems to facilitate the sharing of good-quality data sources.

**5. Privacy and data protection:** Privacy and data protection should be considered during the design and deployment of AI systems. Early in the development process, developers should consider gaining a good understanding of applicable data protection regulations and privacy laws and should ensure that the development process meets or exceeds such legal requirements. It is also important to consider implementing a compliance programme that addresses risks and ensures that the privacy and cybersecurity practices take into account potential harm as well as the enforcement environment.

**6. Engagement and collaboration:** During development of the AI innovation and deployment roadmap it is important to consider the development of accessible and informative platforms that facilitate engagement and collaboration among key stakeholders, where applicable and appropriate. It is fundamental to consider streamlining the oversight process for AI regulation through such engagement and collaboration in order to accelerate practice-changing advances in AI...

:::::: :::::::

# **Polio – PHEIC**

#### Polio this week as of 18 Oct 2023 - GPEI Headlines [Selected]

:: Tuesday, 24 October is World Polio Day, a chance to raise awareness and resources to help deliver a polio-free world in the very near term. To mark the day, partners and stakeholders around the world are organizing events, bringing together public and civil society in a common goal. For all individual eradicators and stakeholders: thank you for everything you do to make the dream of a polio-free world a reality. If you would like to make a personal, voluntary donation towards the effort, we would invite you to contribute via Rotary International's <u>End Polio Now</u> campaign, a key partner alongside WHO and others in the <u>Global Polio Eradication Initiative</u>. Each donation made to Rotary's End Polio Now effort is matched 2:1 by the Bill & Melinda Gates Foundation to maximise its effect. As such, if you give US\$10 to the effort, as an example, the amount becomes US\$30, and with that, 60 children will be vaccinated in the remaining affected countries. Thank you for everything that you do! We wish you a very successful World Polio Day!

:: The Global Polio Eradication Initiative would like to offer our heartfelt congratulations to Professor Rose Leke for receiving the <u>2023 Virchow Prize for Global Health</u>, for her outstanding contributions to advancing global health, including polio eradication. Professor Leke is the Chair of the Africa Regional Certification Commission and member of the Global Commission for Certification of Poliomyelitis Eradication (GCC).

Summary of new polioviruses this week, cases and positive environmental isolates:

- Cameroon: two cVDPV2 positive environmental samples
- Central African Republic: one cVDPV2 case
- Côte d'Ivoire: two cVDPV2 cases and four positive environmental samples
- DR Congo: three cVDPV1 and three cVDPV2 cases, two cVDPV2 positive environmental samples
- Madagascar: three cVDPV1 positive environmental samples
- Mali: one cVDPV2 case
- Yemen: one cVDPV2 case

# .....

.....

# Coronavirus [COVID-19]

https://www.who.int/emergencies/diseases/novel-coronavirus-2019

 Numbers at a glance

 Last update: 18 Oct 2023

 Confirmed cases ::
 771 407 825

 Confirmed deaths ::
 6 972 152

 Vaccine doses administered:
 13 516 282 548

#### Our World in Data


Coronavirus (COVID-19) Vaccinations [Accessed 21 Oct 2023]

:: <u>70.5%</u> of the world population has received at least one dose of a COVID-19 vaccine.

- :: <u>13.52 billion doses</u> have been administered globally, and <u>37,306</u> are now administered each day.
- :: <u>32.6%</u> of people in low-income countries have received at least one dose.

#### Daily COVID-19 vaccine doses administered

7-day rolling average. All doses, including boosters, are counted individually.



# .....

#### Contents [click to move among sections]

- :: <u>Milestones, Perspectives</u>
- :: <u>WHO</u>
- :: Organization Announcements
- :: <u>Journal Watch</u>
- :: <u>Pre-Print Servers</u>

:::::: :::::::

•••••

WHO & Regional Offices [to 21 Oct 2023]

https://www.who.int/news

Selected News/Announcements/Statements 21 October 2023 Statement

Joint statement by UNDP, UNFPA, UNICEF, WFP and WHO on humanitarian supplies crossing into Gaza

20 October 2023 Departmental news WHO and ECHO discuss the way forward in strengthening their partnership and innovative ways of cooperation

20 October 2023 Departmental news <u>Türkiye regulatory system becomes fourteenth country to reach WHO Maturity Level 3</u>

19 October 2023 News release

WHO releases new list of essential diagnostics; new recommendations for hepatitis E virus tests, personal use glucose meters

19 October 2023 Departmental news

13 critical interventions that support countries to address antimicrobial resistance in human health

19 October 2023 News release WHO outlines considerations for regulation of artificial intelligence for health

17 October 2023 Statement WHO statement on attack on Al Ahli Arab Hospital and reported large-scale casualties

17 October 2023 Departmental news First meeting of the Technical Advisory Group on Genomics

17 October 2023 Departmental news <u>United Nations partners call for investments in self-care interventions to improve sexual</u> <u>and reproductive health</u>

17 October 2023 Statement Health leaders at the WHS support WHO commitment to build climate resilient, low carbon sustainable health systems (ATACH)

16 October 2023 Departmental news <u>WHO announces the elimination of lymphatic filariasis as a public health problem in the</u> <u>Lao People's Democratic Republic</u>

16 October 2023 Departmental news <u>WHO announces the release of ScreenTB - a web-based tool to help countries prioritize</u> <u>action for TB screening and prevention</u>

.....

WHO Regional Offices Selected Press Releases, Announcements WHO African Region No new digest content identified.

#### WHO Region of the Americas PAHO

:: 18 Oct 2023 <u>PAHO joins forces with Canada to reverse declining immunization against vaccine-preventable</u> <u>diseases in Haiti</u>

Washington, D.C., 18 October 2023 (PAHO) – The Pan American Health Organization (PAHO) and the Government of Canada announced today the launch of a joint initiative to support Haiti to expand vaccination against potentially lethal vaccine-preventable diseases, including polio, measles, diphtheria and tetanus The partnership, which is part of...

# :: 17 Oct 2023

IARC and PAHO launch the 1st edition of the Latin America and the Caribbean Code Against Cancer Lyon, France / Washington DC, 17 October 2023 – The Pan American Health Organization (PAHO) and the International Agency for Research on Cancer (IARC) today launched the first edition of the Latin America and the Caribbean Code Against Cancer. The new Code, which forms part of the World Code Against Cancer, aims to help reduce the burden of cancer...

:: 17 Oct 2023

PAHO Director underscores transatlantic partnerships to address present and future health challenges

Berlin, Germany, 17 October 2023 (PAHO) - At the 2023 World Health Summit in Berlin, the Pan American Health Organization (PAHO) Director, Jarbas Barbosa, highlighted the need for strong partnerships across regions to increase health access and equity, especially as countries work to increase preparedness and response to future health threats. "...

# WHO South-East Asia Region SEARO

No new digest content identified.

# WHO European Region EURO

21 October 2023 News release
<u>Unlocking the future of healthy ageing: The Lisbon Outcome Statement</u>
20 October 2023 News release
<u>Addressing the growing needs of Kazakhstan's digital health workforce</u>
18 October 2023 News release
<u>Despite progress, challenges persist in advancing sexual and reproductive health and rights in the WHO European Region</u>

# WHO Western Pacific Region

:: 20 October 2023 Media release <u>Region's health leaders agree on actions to enhance communication for health, strengthen a...</u>
:: 19 October 2023 Media release <u>Health leaders take steps to strengthen health security in Asia-Pacific</u>
:: <u>17 October 2023 News release</u> <u>Dr Saia Ma'u Piukala nominated to lead WHO Western Pacific Region</u>

.....

# WHO - Emergency situation reports

#### Multi-country outbreak of mpox, External situation report#29 – 20 October 2023

:::::

#### Disease Outbreak News (DONs)

Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.

# 18 October 2023 | Diphtheria - Guinea

# 16 October 2023 | Dengue - Chad

.....

#### Weekly Epidemiological Record

https://www.who.int/publications/journals/weekly-epidemiological-record Vol. 98, No. 41, pp. 489–502 13 October 2023 PDF: <u>https://iris.who.int/bitstream/handle/10665/373356/WER9841-eng-fre.pdf</u> *Contents* 471 Global program to eliniate lymphatic filariasis: progress report, 2022

.....

#### **New WHO Publications**

https://www.who.int/publications/i Selected 20 October 2023 Medication safety for look-alike, sound-alike medicines

20 October 2023 Medication safety for look-alike, sound-alike medicines

19 October 2023

People-centred approach to addressing antimicrobial resistance in human health

17 October 2023 <u>The use of next-generation sequencing for the surveillance of drug-resistant</u> <u>tuberculosis: an implementation...</u>

17 October 2023 Tuberculosis action plan for the WHO European Region, 2023–2030

17 October 2023 Self-care interventions for sexual and reproductive health and rights to advance universal health coverage:...

16 October 2023 WHO Guidelines for malaria

16 October 2023 Joint external evaluation of IHR core capacities of the Kingdom of Thailand: mission report, 31 October-4...

.....

#### USA – HHS, FDA, CDC

HHS

<u>News</u> No new digest content identified.

#### FDA

Press Announcements FDA Roundup: October 20, 2023

October 20, 2023

... On Thursday, the FDA added <u>171 devices to the list</u> of artificial intelligence and machine learning (AI/ML)-enabled devices legally marketed in the United States by 510(k) clearance, granted De Novo request, or premarket approval. With this update, the FDA also added insights about trends based on analyses of the data. This list is not meant to be an exhaustive or comprehensive

resource of AI/ML-enabled medical devices. Rather, it is a list of AI/ML-enabled devices across medical disciplines, based on publicly available information. The FDA maintains this list to increase transparency about AI/ML-enabled devices in this rapidly progressing field.

# FDA VRBPAC

<u>Advisory Committee Calendar</u> No new meetings scheduled.

# **CDC/ACIP [U.S.]** [to 21 Oct 2023]

http://www.cdc.gov/media/index.html Latest News Releases No new digest content identified.

# **ACIP Meetings**

*Next ACIP Meeting* October 25-27.

# **MMWR Weekly**

https://www.cdc.gov/mmwr/index2023.html October 20, 2023 / No. 42

PDF of this issue

- <u>Preventable Deaths During Widespread Community Hepatitis A Outbreaks United States,</u> 2016–2022
- Progress Toward Measles and Rubella Elimination Indonesia, 2013–2022
- <u>Use of Updated COVID-19 Vaccines 2023–2024 Formula for Persons Aged ≥6 Months:</u> <u>Recommendations of the Advisory Committee on Immunization Practices — United States,</u> <u>September 2023</u>

.....

.....

#### Europe

#### **European Medicines Agency [EMA]**

https://www.ema.europa.eu/en/search/search/ema\_editorial\_content/ema\_news?sort=field\_ema\_c omputed\_date\_field&order=desc News & Press Releases No new digest content identified.

#### .....

#### **European Centre for Disease Prevention and Control**

https://www.ecdc.europa.eu/en News/Updates/Reports/Publications [Selected] Scientific and technical publications Communicable disease threats report, 15-22 October 2023, week 42 Monitoring - 20 Oct 2023

Scientific and technical publications

Evidence-based advice processes for long-term care facilities in the COVID-19 pandemic - Aggregate report from the After-Action reviews in Georgia and Norway Assessment - 19 Oct 223 Scientific and technical publications Standard laboratory protocols for SARS-CoV-2 characterisation Guidance - 18 Oct 2023

Scientific and technical publications
Evidence-based advice processes for long-term care facilities in the COVID-19 pandemic
- Report from the after-action review (AAR) in Norway
Accounter 17 Oct 2022

Assessment - 17 Oct 2023

:::::: :::::::

Africa CDC [to 21 Oct 2023] <u>http://www.africacdc.org/</u> *Press Releases, Statements [Selected] Press Releases* Joint Statement on Action plan to drive equitable expansion of immunisation in Africa 16 October 2023

.....

China CDC http://www.chinacdc.cn/en/

#### National Health Commission of the People's Republic of China [to 21 Oct 2023]

<u>http://en.nhc.gov.cn/</u> *News No new digest content identified.* 

#### National Medical Products Administration – PRC [to 21 Oct 2023]

<u>http://english.nmpa.gov.cn/</u> *News No new digest content identified.* 

#### China CDC Weekly Reports: Current Volume (5)

#### 2023-10-20 / No. 42 *EPIDEMIOLOGICAL TRANSITION IN INFECTIOUS DISEASES ISSUE* View PDF of this issue

- Preplanned Studies: Changing Patterns of Mortality in Viral Hepatitis China, 1987–2021
- <u>Preplanned Studies: Trends and Patterns of Respiratory Tuberculosis Mortality in Rural and</u> <u>Urban — China, 1987–2021</u>
- <u>Preplanned Studies: Trends in Mortality and Prevalence of Reported HIV/AIDS Cases China,</u> 2002–2021
- <u>Perspectives: Epidemiological Shifts in Infectious Diseases in China: Implications and Policy</u> <u>Recommendations</u>

.....

.....

Contents [click to move among sections]

:: <u>Milestones, Perspectives</u>

:: <u>WHO</u>

*:: <u>Organization Announcements</u> :: <u>Journal Watch</u> <i>:: <u>Pre-Print Servers</u>* 

::::::

#### **Organization Announcements**

# Paul G. Allen Frontiers Group [to 21 Oct 2023] https://alleninstitute.org/news-press/ News No new digest content identified.

#### BMGF - Gates Foundation [to 21 Oct 2023]

https://www.gatesfoundation.org/ideas/media-center Press Releases and Statements No new digest content identified.

#### Bill & Melinda Gates Medical Research Institute [to 21 Oct 2023]

#### https://www.gatesmri.org/news

The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people News: Articles and Publications No new digest content identified.

#### CARB-X [to 21 Oct 2023] https://carb-x.org/ News

No new digest content identified.

#### **CEPI – Coalition for Epidemic Preparedness Innovations** [to 21 Oct 2023]

http://cepi.net/ Latest News

#### Forecasting viral mutations

Advances in AI are making it possible to quickly and effectively model potential viral vaccine targets News

20 Oct 2023

#### Australia's Doherty Institute joins CEPI's laboratory network to speed up development of epidemic and pandemic vaccines

Doherty becomes the first laboratory in Australia to join the network, the largest global group set up to standardise testing of vaccine candidates in preclinical and clinical trials. 18 Oct 2023

#### **CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES** [to

21 Oct 2023] https://cioms.ch/ News; Publications; Events No new digest content identified.

#### DARPA – Defense Advanced Research Projects Agency [U.S.] [to 21 Oct 2023

<u>https://www.darpa.mil/news</u> *News No new digest content identified.* 

#### Duke Global Health Innovation Center [to 21 Oct 2023]

https://dukeghic.org/ News No new digest content identified.

#### **EDCTP** [to 21 Oct 2023]

http://www.edctp.org/

The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials No new digest content identified.

#### Emory Vaccine Center [to 21 Oct 2023]

http://www.vaccines.emory.edu/ Vaccine Center News No new digest content identified.

#### European Vaccine Initiative [to 21 Oct 2023]

http://www.euvaccine.eu/ Latest News, Events No new digest content identified.

#### Evidence Aid [to 21 Oct 2023]

*Evidence Aid aims to save lives and livelihoods in disasters by providing decision-makers with the best available evidence and by championing its use.* <u>http://www.evidenceaid.org/</u> *Resources [Selected]* <u>Health-related disaster communication and social media (research up to 2016)</u> Added October 19, 2023

Population density and the transmission of COVID-19 and other respiratory viruses (search done in October 2020) Added October 17, 2023

#### Fondation Merieux [to 21 Oct 2023]

http://www.fondation-merieux.org/

News, Events

Lessons from COVID-19 vaccine introduction: The current state of behavioral & social determinants of vaccination

October 30 - November 1, 2023 - Les Pensières, Center for Global Health, Veyrier-du-Lac (France) The Mérieux Foundation's Vaccine Acceptance Event Series aims to:

:: Establish and maintain dialogue and increase multi-sectoral efforts.

:: Promote vaccination acceptance, understand trust bubbles and strengthen the resilience of immunization programs widely affected globally facing important challenges during the pandemic of coronavirus disease 2019, or COVID-19.

Gavi [to 21 Oct 2023] https://www.gavi.org/ News Releases 19 October 2023 Gavi welcomes appointment of global health leader Prof Helen Rees as Chair of Vaccine Investment Strategy Steering Committee

16 October 2023 Action plan to drive equitable expansion of immunisation in Africa

# GE2P2 Global Foundation [to 21 Oct 2023]

www.ge2p2.org

*News/Analysis/Publications-Digests/Statements* 

:: Vaccines and Global Health: The Week in Review - Current edition

:: Informed Consent: A Monthly Review - October 2023

- :: <u>Genomic Medicine Governance, Ethics, Policy, Practice: A Monthly Digest</u> Oct 2023
- :: Public Consultations Watch :: Global Calls for Input/Public Comment 06 Oct 2023 Issue 08

#### **GHIT Fund** [to 21 Oct 2023]

https://www.ghitfund.org/newsroom/press

*Press Releases* October 12, 2023

Global Health Innovative Technology Fund and Institut Pasteur de Dakar Announce New Partnership to Advance Research and Development for New Diagnostics and Vaccines in LMICs

... Building on their respective expertise and resources, GHIT Fund and IPD will collaborate to foster the development of cutting-edge solutions to combat infectious diseases in Africa and beyond. Through this new partnership, the two institutions will accelerate product development for neglected diseases in LMICs in the areas of therapeutics, vaccine and diagnostic research and development and strengthen collaboration to support low-cost vaccine and diagnostics manufacturing in LMICs through technology transfer and know-how sharing from/with Japanese pharmaceutical companies and academia. This will not only improve access to essential health technologies, but also contribute to the development of a sustainable local health infrastructure...

https://www.theglobalfund.org/en/news/ News & Stories 16 October 2023 Global Fund and Siemens Healthineers to Accelerate Adoption of Artificial Intelligence for Tuberculosis Diagnosis

Siemens Healthineers and the Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund), announced a partnership at the World Health Summit today to accelerate the use of artificial intelligence (AI) in diagnosing tuberculosis (TB), a prev...

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 21 Oct 2023] https://www.glopid-r.org/news/ News No new digest content identified.

#### Hilleman Laboratories [to 21 Oct 2023]

<u>http://www.hilleman-labs.org/</u> *News & Insights No new digest content identified.* 

#### HHMI - Howard Hughes Medical Institute [to 21 Oct 2023]

<u>https://www.hhmi.org/news</u> *Press Room No new digest content identified.* 

#### Human Vaccines Project [to 21 Oct 2023]

http://www.humanvaccinesproject.org/ News No new digest content identified.

IAVI [to 21 Oct 2023] <u>https://www.iavi.org/</u> *Latest News, Features* October 13, 2023 <u>Behind the Relentless Pursuit of an HIV Vaccine</u> Elevating Lab Standards and Embracing Good Clinical Laboratory Practice in Sub-Saharan Africa

**INSERM** [to 21 Oct 2023] https://www.inserm.fr/en/home/ Press Releases No new digest content identified.

#### International Coalition of Medicines Regulatory Authorities [ICMRA]

http://www.icmra.info/drupal/en/news Selected Statements, Press Releases, Research No new digest content identified.

# ICH - International Council for Harmonisation of Technical Requirements for

Pharmaceuticals for Human Use [to 21 Oct 2023] https://www.ich.org/page/press-releases News/Pubs/Press Releases [Selective] No new digest content identified.

ICRC [to 21 Oct 2023] https://www.icrc.org/en/whats-new What's New [Selected] Protecting Civilians Against Digital Threats During Armed Conflict Final report of the ICRC's Global Advisory Board on Digital Threats During Armed Conflicts.

19-10-2023 | Report

#### IFFIm

<u>http://www.iffim.org/</u> *Press Releases/Announcements No new digest content identified.* 

IFRC [to 21 Oct 2023] http://media.ifrc.org/ifrc/news/press-releases/ Press Releases [Selected] Press release 21/10/2023 IFRC welcomes first aid into Gaza but says much more is needed

Press release 16/10/2023 Humanitarian needs in Sudan grow as funding gap widens, IFRC warns

**Institut Pasteur** [to 21 Oct 2023] https://www.pasteur.fr/en/press-area *Press Documents No new digest content identified.* 

#### ISC / International Science Council [to 21 Oct 2023]

<u>https://council.science/current/</u> ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils. News No new digest content identified.

#### International Union of Immunological Societies (IUIS)

https://iuis.org/ News/Events [Selected]

#### 2023 International Society for Vaccines (ISV) Annual Congress

Dates: 22 – 24 October 2023 Lausanne, Switzerland

**IVAC** [to 21 Oct 2023] https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html Updates; Events No new digest content identified.

**IVI** [to 21 Oct 2023]

http://www.ivi.int/ IVI News & Announcements

# **IVI convenes inaugural Global Council meeting in Seoul**

October 20, 2023, SEOUL, Republic of Korea — The International Vaccine Institute (IVI), an international organization with a mission to discover, develop, and deliver safe, effective, and affordable vaccines for global health, held its inaugural Global Council meeting yesterday in Seoul, establishing a new representative body for all IVI State Parties. On the first day of the two-day meeting, country delegates focused discussions on the importance of robust vaccine ecosystems in every part of the world in an era of increasing outbreaks of infectious diseases...

#### Johns Hopkins Center for Health Security [to 21 Oct 2023]

https://www.centerforhealthsecurity.org/news/center-news/ Center News [Selected]

October 20, 2023

<u>Center for Health Security submits Senate RFI to reform and strengthen the Centers for</u> <u>Disease Control and Prevention (CDC)</u>

The Johns Hopkins Center for Health Security today provided feedback and suggestions in response to a RFI from Senator Bill Cassidy, on how Congress can help reform and strengthen the CDC.

October 16, 2023

<u>Center for Health Security faculty respond to White House Office of Science and</u> <u>Technology Policy RFI on Dual Use Research of Concern and Potential Pandemic</u> <u>Pathogen Care and Oversight Policy Framework</u>

A group of public health and security experts responded to a Request for Information today from the White House OSTP regarding potential changes to the Policies for Federal and Institutional Oversight of Life Sciences Dual Use Research of Concern (DURC) and Potential Pandemic Pathogen Care and Oversight (P3CO) Policy Framework.

#### MSF/Médecins Sans Frontières\_[to 21 Oct 2023]

<u>http://www.msf.org/</u> Latest [Selected Announcements] Gaza-Israel war

#### Unconditional humanity needs to be restored in Gaza

Opinion 17 Oct 2023

... Despite the incredible needs, the widespread bombing and the impossibility to bring in supplies has forced us to suspend most of our activities. Our teams inside and outside of Gaza are doing the best they can to respond.

As a medical and humanitarian organisation, we want to do so much more. Today this is just impossible.

#### National Academy of Medicine - USA [to 21 Oct 2023]

https://nam.edu/programs/ News [Selected] Statement by NAM President Victor Dzau on Humanitarian Crisis in Israel and Gaza October 19, 2023

National Academy of Sciences - USA [to 21 Oct 2023] https://www.nationalacademies.org/newsroom? News No new digest content identified.

#### National Vaccine Program Office - U.S. HHS [to 21 Oct 2023]

https://www.hhs.gov/vaccines/about/index.html Upcoming Meetings/Latest Updates No new digest content identified.

NIH [to 21 Oct 2023] http://www.nih.gov/ News Releases No new digest content identified.

PATH [to 21 Oct 2023] https://www.path.org/media-center/ Press Releases Join PATH at the 2023 American Society of Tropical Medicine and Hygiene Annual Meeting

PATH will join partners from around the world to exchange the latest research at this annual gathering of tropical medicine and global health professionals. This year's meeting will be held in Chicago from October 18-22.

#### Rockefeller Foundation [to 21 Oct 2023]

https://www.rockefellerfoundation.org/ Selected Reports/Press Releases No new digest content identified.

#### Sabin Vaccine Institute [to 21 Oct 2023]

https://www.sabin.org/press/ Latest News & Press Releases Press Releases Sabin Vaccine Institute Begins Phase 2 Clinical Trial for Marburg Vaccine in Uganda October 19, 2023 ...Healthy volunteers received the single-dose vaccine at Makerere University Walter Reed Project (MUWRP) in Kampala, Uganda today...

**UNAIDS** [to 21 Oct 2023] http://www.unaids.org/en Selected Press Releases/Reports/Statements No new digest content identified.

UNICEF [to 21 Oct 2023] https://www.unicef.org/media/press-releases Latest press releases, news notes and statements Statement 21 October 2023 Joint statement by UNDP, UNFPA, UNICEF, WFP and WHO on humanitarian supplies crossing into Gaza https://www.unicef.org/press\_releases/inint\_statement\_undp\_unicef\_wfp\_and\_who

https://www.unicef.org/press-releases/joint-statement-undp-unfpa-unicef-wfp-and-whohumanitarian-supplies-crossing-gaza-0

NEW YORK/GENEVA/ROME, 21 October 2023 – "A first, but limited, shipment of life-saving humanitarian supplies from the United Nations and the Egyptian Red Crescent entered Gaza today on 20 trucks, passing through the Rafah Crossing. "It will provide an urgently needed lifeline to some of the hundreds of thousands of civilians, mostly women and...

Unitaid [to 21 Oct 2023] https://unitaid.org/ Featured News No new digest content identified.

#### Vaccine Equity Cooperative [nee Initiative] [to 21 Oct 2023]

https://vaccineequitycooperative.org/news/ News No new digest content identified.

#### Vaccination Acceptance & Demand Initiative [Sabin) [to 21 Oct 2023]

https://www.vaccineacceptance.org/ Announcements, Blog No new digest content identified.

# Vaccine Confidence Project [to 21 Oct 2023]

http://www.vaccineconfidence.org/ News, Research and Reports No new digest content identified.

Vaccine Education Center – Children's Hospital of Philadelphia [to 21 Oct 2023] http://www.chop.edu/centers-programs/vaccine-education-center News Fall 2023 Vaccines: Considering Flu, COVID-19 and RSV Oct 1, 2023

For the first time, vaccines are available to prevent three typical winter respiratory viruses: influenza, COVID-19 and RSV. In this short video, Dr. Offit talks about the vaccines that protect against each of these viruses and who should get them.

Wellcome Trust [to 21 Oct 2023] https://wellcome.ac.uk/news News. Opinion, Reports No new digest content identified.

The Wistar Institute [to 21 Oct 2023] https://www.wistar.org/news/press-releases Press Releases Press Release Oct. 17, 2023 Dean Stoios Joins The Wistar Institute as Chief Financial Officer

PHILADELPHIA (October 17, 2023) – The Wistar Institute, a global leader in biomedical research in cancer, immunology and infectious diseases, announces the appointment of Dean Stoios as Chief Financial Officer.

World Bank [to 015 Oct 2022] http://www.worldbank.org/en/news/all All News [Selected] Ending Poverty is our First Global Goal, and We are Off Track

We are at a critical juncture today in the fight against poverty. Despite decades of hard-won development progress, a world free of poverty remains out of sight. Ten years ago, the outlook appeared more... Date: October 17, 2023 Type: Opinion

#### WFPHA: World Federation of Public Health Associations [to 21 Oct 2023]

<u>https://www.wfpha.org/</u> *Latest News - Blog No new digest content identified.* 

#### World Medical Association [WMA] [to 21 Oct 2023]

https://www.wma.net/news-press/press-releases/ Press Releases The World Medical Association stands firmly for the principles of medical neutrality as defined by the Geneva Convention, and calls on all parties to respect International Law and the integrity of unrelated civilian populations 15.10/2023

World Organisation for Animal Health [to 21 Oct 2023] https://www.oie.int/en/ Press Releases, Statements Statements

# African swine fever: WOAH warns Veterinary Authorities and pig industry of risk from use of sub-standard vaccines

18 Oct 2023

In this context, the World Organisation for Animal Health (WOAH) stresses the importance of the use of only high-quality ASF vaccines with proven efficacy and safety, and which have been subject to regulatory evaluation and approval in accordance with <u>WOAH international standards</u>...

#### .....

#### ARM [Alliance for Regenerative Medicine] [to 21 Oct 2023]

https://alliancerm.org/press-releases/ Selected Press Releases No new digest content identified.

**BIO** [to 21 Oct 2023] https://www.bio.org/press-releases Press Releases

New USITC report shows "no credible evidence" supporting a TRIPs waiver expansion October 17, 2023

The United States International Trade Commission (USITC) today released its "COVID-19 Diagnostics and Therapeutics: Supply, Demand, and TRIPS Agreement Flexibilities" report. The report aims to analyze various issues and information gaps concerning...

#### DCVMN – Developing Country Vaccine Manufacturers Network [to 21 Oct 2023]

<u>http://www.dcvmn.org/</u> *News; Upcoming events No new digest content identified.* 

#### ICBA – International Council of Biotechnology Associations [to 21 Oct 2023]

https://internationalbiotech.org/news/ News No new digest content identified.

**IFPMA** [to 21 Oct 2023]

https://ifpma.org/

Selected Press Releases/Statements

Statement 18 Oct 2023

IFPMA statement at the 74th Session of the WHO Regional Committee for the Western Pacific

On 18 October 2023 at the 74th Session of the WHO Regional Committee for the Western Pacific in Manila, Philippines, IFPMA submitted a statement on agenda item 11: Health security.

#### Statement 17 Oct 2023

IFPMA Statement at the WIPO Standing Committee on the Law of Patents (SCP) 35

On 17 October in Geneva, IFPMA submitted a statement at the WIPO Standing Committee on the Law of Patents (SCP) 35.

Statement 17 Oct 2023

#### <u>Innovative pharmaceutical industry statement on draft WHO Pandemic Treaty: We need</u> to preserve what went well and address what went wrong

On 16 October 2023, IFPMA issued a statement in response to draft WHO Pandemic Treaty.

#### External study 16 Oct 2023

The value of vaccines to mitigate antimicrobial resistance

A report published by One Health Trust makes an urgent call for increasing vaccination coverage to tackle the growing threat of antimicrobial resistance (AMR) in low- and middle-income countries.

#### International Alliance of Patients' Organizations – IAPO [to 21 Oct 2023]

https://www.iapo.org.uk/news/topic/6 Press and media [Selected] No new digest announcements identified

#### International Generic and Biosimilar Medicines Association [IGBA]

https://www.igbamedicines.org/ News No new digest announcements identified

**PhRMA** [to 21 Oct 2023]

http://www.phrma.org/

Press Releases

PhRMA Statement on U.S. International Trade Commission Report on Expanding the TRIPS Waiver

WASHINGTON, D.C. (October 17, 2023) – Today, Pharmaceutical Research and Manufacturers of America (PhRMA) Deputy Vice President for Public Affairs Megan Van Etten issued the following statement in response to the U.S. International Trade Commission (USITC) report on "COVID-19 Diagnostics and Therapeutics: Supply, Demand, and TRIPS Agreement Flexibilities:"

"The COVID-19 public health emergency is over and across the world there is an abundance of affordable and often free treatments. TRIPS waiver expansion is unnecessary and would harm American workers, patients and innovation by handing over IP to foreign competitors. It's past time for the Biden administration and other world leaders to move beyond this ideological debate and focus on real global health challenges."...

:::::: :::::::

# Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements

AstraZeneca <u>Press Releases</u> \_- No new digest announcements identified

Bharat Biotech <u>Press Releases</u> - No new digest announcements identified

**BioCubaFarma** – Cuba <u>Últimas Noticias</u> - Website not responding at inquiry

**Biological E** 

News - No new digest announcements identified

#### **BioNTech**

Press Releases

19 October 2023

**BioNTech Expands Late-Stage Clinical Oncology Portfolio with Initiation of further Phase 2 Trial with mRNA-based Individualized Neoantigen Specific Immunotherapy in New Cancer Indication** 

#### **Boehringer**

Press Releases - No new digest announcements identified

#### CanSinoBIO

<u>News</u> - Website not responding at inquiry

#### CIGB

Latest News - No new digest announcements identified

#### Cinnagen

<u>Recent News</u> - No new digest announcements identified

#### Clover Biopharmaceuticals - China

News - No new digest announcements identified

#### Curevac [Bayer Ag – Germany]

News - No new digest announcements identified

#### Gamaleya National Center/Sputnik

<u>Latest News and Events</u> - No new digest announcements identified <u>https://sputnikvaccine.com/</u> - No new digest announcements identified

#### GSK

<u>Press releases for media</u> 18 October 2023 ViiV Healthcare to present 23 abstracts from innovative HIV treatment and prevention portfolio at EACS 2023

Key data to be presented include long-term and real-world data, including long-acting and 2-drug regimens.

#### IMBCAMS, China

<u>Home</u> - Website not responding at inquiry

#### Janssen/JNJ

<u>Press Releases</u> - No new digest announcements identified

#### Merck

<u>News releases</u> - No new digest announcements identified

Moderna <u>Press Releases</u> - No new digest announcements identified

#### Nanogen

News - No new digest announcements identified

#### Novartis

<u>News</u> - No new digest announcements identified

#### Novavax

<u>Press Releases</u> Oct 18, 2023 <u>COVID-19</u> <u>Novavax Receives Full Marketing Authorization for Prototype COVID-19 Vaccine</u> <u>Nuvaxovid™ ▼ in United Kingdom</u>

Oct 18, 2023 COVID-19 Novavax's Prototype COVID-19 Vaccine Nuvaxovid<sup>™</sup> Receives Full Approval in Singapore

Oct 16, 2023 Statement COVID-19 Novavax Statement on 2023-2024 COVID-19 Vaccination Season

#### Pfizer

<u>Recent Press Releases</u> 10.20.2023

FDA Approves PENBRAYA<sup>™</sup>, the First and Only Vaccine for the Prevention of the Five Most Common Serogroups Causing Meningococcal Disease in Adolescents

:: PENBRAYA<sup>™</sup> provides the broadest serogroup coverage (meningococcal groups A, B, C, W and Y) of any meningococcal vaccine available in the U.S. and has the potential to help simplify complex vaccination schedule in the U.S.

:: The FDA's decision is based on data from Phase 2 and Phase 3 trials, which demonstrated that PENBRAYA has robust immunogenicity non-inferior to Trumenba® + Menveo® for all serogroups and was well-tolerated with a favorable safety profile

:: The vaccine further advances Pfizer's vaccine portfolio and builds on more than 20 years of expertise and knowledge in the prevention of meningococcal disease

#### **R-Pharm**

https://rpharm-us.com/index.php [No news or media page identified]

#### Sanofi Pasteur

Press Releases

Press Release: Sanofi delivers first medicines from Global Health Unit's Impact brand portfolio

Paris, October 19, 2023. Sanofi has delivered the first medicines from its Global Health Unit's notfor-profit Impact brand portfolio to the Republic of Djibouti. Enoxaparin Sodium Impact is an anticoagulant medicine indicated for the treatment of venous thromboembolism including deep vein thrombosis, a potentially lethal disease often underdiagnosed on the African continent. With this first shipment to Djibouti, Sanofi delivers on its commitment to improve and accelerate affordable and sustainable access to quality medicines, vaccines and healthcare for underserved populations...

#### Serum Institute of India

<u>NEWS & ANNOUNCEMENTS</u> - No new digest announcements identified

#### Sinopharm/WIBPBIBP

<u>News</u> - No new digest announcements identified [English translation function not operating]

#### Sinovac

Press Releases

# SINOVAC's Vital Role in the Belt and Road Initiative: A Lifeline in the Fight Against Infectious Diseases

#### 2023-10-20

October 20, 2023, Beijing, China – Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today shared its accomplishments in collaboration with the Belt and Road Initiative (BRI) countries, demonstrating its commitment to the initiative's guiding principle of "planning together, building together, and benefiting together."

SINOVAC has provided over 1.2 billion doses of vaccines to 62 BRI countries, offering protection against a range of infectious diseases such as COVID-19, hepatitis A, influenza and varicella, as well as pneumococcal infections.

Behind these remarkable figures are 20 research projects in 10 BRI countries, 95 marketing approvals and emergency use authorizations, 17 technology licensing agreements for vaccine production signed in 12 BRI countries, and localized production programs in seven...

#### **SK Biosciences**

<u>Press Releases</u>

Updated Novavax COVID-19 Vaccine Is Submitted for Emergency Use Authorization in the Republic of Korea

SK bioscience plans to introduce the only updated protein-based non-mRNA, COVID vaccine for South Ko...

2023.10.20

#### Takeda

<u>Newsroom</u> - No new digest announcements identified

#### Valneva

<u>Press Releases</u> - No new digest announcements identified

#### Vector State Research Centre of Viralogy and Biotechnology

<u>Home</u> - Website not responding [404 error]

#### WestVac Biopharma

Media - No new digest announcements identified

#### Zhifei Longcom, China

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.] [No website identified]

.....

#### Contents [click to move among sections]

- :: <u>Milestones, Perspectives</u>
- :: <u>WHO</u>
- :: Organization Announcements
- *:: <u>Journal Watch</u>*
- :: <u>Pre-Print Servers</u>

#### Journal Watch

*Vaccines and Global Health: The Week in Review* continues its weekly scanning of key peerreviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: <u>david.r.curry@centerforvaccineethicsandpolicy.org</u>

#### **AJOB Empirical Bioethics**

Volume 14, 2023 Issue 3 <u>https://www.tandfonline.com/toc/uabr21/current</u> [Reviewed earlier]

#### **AMA Journal of Ethics**

Volume 25, Number 10: E719-790 https://journalofethics.ama-assn.org/issue/geriatric-psychiatry

#### Geriatric Psychiatry

Twenty percent of the US population is expected to be 65 years of age or older by 2030. Ageism's pervasiveness in US culture means it is also pervasive in health care and a cause of inequity that profoundly undermines older adults' quality of life. Independence and autonomy losses tend to accompany aging for all of us. Older adults are vulnerable to exploitation and are exposed to late-life stressors that affect their mental health, accompany compromise or loss of independence and autonomy, and tend to track declines in general health and cognitive function. This theme issue investigates reasons why diminishing numbers of geriatric mental health clinicians should draw clinical, ethical, and legal attention to whether and how well US health care and its workforce is prepared to deliver the volume and quality of care older adults deserve.

#### **American Journal of Human Genetics**

Oct 05, 2023 Volume 110 Issue 10 p1607-1826 https://www.cell.com/ajhg/current [Reviewed earlier]

#### **American Journal of Infection Control**

October 2023 Volume 51 Issue 10 p1083-1200 <u>http://www.ajicjournal.org/current</u> [Reviewed earlier]

#### **American Journal of Preventive Medicine**

October 2023 Volume 65 Issue 4 p551-762 <u>https://www.ajpmonline.org/current</u> [Reviewed earlier]

#### .....

#### **American Journal of Public Health**

November 2023 113(11) <u>http://ajph.aphapublications.org/toc/ajph/current</u> [Reviewed earlier]

#### American Journal of Tropical Medicine and Hygiene

Volume 109 (2023): Issue 3 (Sep 2023) https://www.ajtmh.org/view/journals/tpmd/109/2/tpmd.109.issue-3.xml [Reviewed earlier]

#### **Annals of Internal Medicine**

October 2023 Volume 176, Issue 10 <u>https://www.acpjournals.org/toc/aim/current</u> *Ideas and Opinions* <u>More Protection Against Respiratory Viral Infection: Respiratory Syncytial Virus</u> <u>Vaccines for Adults Aged 60 Years and Older</u> Camille Nelson Kotton, MD Pages:1419–1421

#### Artificial Intelligence – An International Journal

Volume 323 October 2023 <u>https://www.sciencedirect.com/journal/artificial-intelligence/vol/323/suppl/C</u> [Reviewed earlier]

#### **BMC Cost Effectiveness and Resource Allocation**

http://resource-allocation.biomedcentral.com/ (Accessed 21 Oct 2023) [No new digest content identified]

#### **BMC Health Services Research**

http://www.biomedcentral.com/bmchealthservres/content (Accessed 21 Oct 2023) [No new digest content identified]

#### **BMC Infectious Diseases**

http://www.biomedcentral.com/bmcinfectdis/content (Accessed 21 Oct 2023) [No new digest content identified]

#### **BMC Medical Ethics**

http://www.biomedcentral.com/bmcmedethics/content (Accessed 21 Oct 2023) [No new digest content identified]

#### **BMC Medicine**

http://www.biomedcentral.com/bmcmed/content (Accessed 21 Oct 2023) [No new digest content identified]

#### **BMC Pregnancy and Childbirth**

http://www.biomedcentral.com/bmcpregnancychildbirth/content (Accessed 21 Oct 2023) [No new digest content identified]

#### **BMC Public Health**

http://bmcpublichealth.biomedcentral.com/articles (Accessed 21 Oct 2023) Understanding multilevel barriers to childhood vaccination uptake among Internally Displaced Populations (IDPs) in Mogadishu, Somalia: a qualitative study

*Disparities in vaccination coverage exist in Somalia with Internally Displaced Persons (IDPs) being among the groups with the lowest coverage. We implemented an adapted Participatory Learning and Action (PLA) ...* Authors: Mohamed Jelle, Andrew J Seal, Hodan Mohamed, Hani Mohamed, Mohamed Sheikh Omar, Sadik Mohamed, Amina Mohamed and Joanna Morrison

Citation: BMC Public Health 2023 23:2018 Content type: Research Published on: 17 October 2023

#### **BMC Research Notes**

http://www.biomedcentral.com/bmcresnotes/content (Accessed 21 Oct 2023) [No new digest content identified]

#### **BMJ Evidence-Based Medicine**

October 2023 - Volume 28 - 5 <u>https://ebm.bmj.com/content/28/5</u> [Reviewed earlier]

#### **BMJ Global Health**

October 2023 - Volume 8 - 10 https://gh.bmj.com/content/8/10 Analysis

Implementing Joint External Evaluations of the International Health Regulations (2005) capacities in all countries in the WHO African region: process challenges, lessons learnt and perspectives for the future (6 October, 2023)

Ibrahima-Soce Fall, Roland Kimbi Wango, Ali Ahmed Yahaya, Mary Stephen, Allan Mpairwe, Miriam Nanyunja, Belinda Louise Herring, Anderson Latt, Janneth Mghamba, Viviane Fossouo Ndoungue, Daniel Yota, Christian Massidi, Amadou Bailo Diallo, Sally-Ann Ohene, Charles Njuguna, Antonio Oke, Georges Alfred Kizerbo, Dick Chamla, Zabulon Yoti, Ambrose Talisuna

Original research

Immunogenicity, safety, usability and acceptability of microarray patches for vaccination: a systematic review and meta-analysis (12 October, 2023) Matthew N Berger, Ellen S Mowbray, Marian W A Farag, Erin Mathieu, Cristyn Davies, Claire Thomas, Robert Booy, Angus H Forster, S Rachel Skinner

Performance of predictive algorithms in estimating the risk of being a zero-dose child in India, Mali and Nigeria (11 October, 2023) Arpita Biswas, John Tucker, Sebastian Bauhoff

Trends in public health emergencies in the WHO African Region: an analysis of the past two decades public health events from 2001 to 2022 (9 October, 2023) Etien Luc Koua, Jobert Richie Nansseu Njingang, Jean Paul Kimenyi, George Sie Williams, Joseph Okeibunor, Sakuya Oka, Abdou Salam Gueye

<u>A critical analysis of COVAX alliance and corresponding global health governance and policy issues: a scoping review</u> (4 October, 2023) Anjali Pushkaran, Vijay Kumar Chattu, Prakash Narayanan

#### **Bulletin of the Atomic Scientists**

September 2023 https://thebulletin.org/magazine/2023-09/ Contents [Reviewed earlier]

#### **Bulletin of the World Health Organization**

Volume 101(10); 2023 Oct 1 <u>https://www.ncbi.nlm.nih.gov/pmc/issues/446112/</u> [Reviewed earlier]

#### Cell

Oct 12, 2023 Volume 186 Issue 21 p4475-4728 <u>https://www.cell.com/cell/current</u> [New issue; No digest content identified]

#### Child Care, Health and Development

Volume 49, Issue 6 Pages: 941-1111 November 2023 https://onlinelibrary.wiley.com/toc/13652214/current [New issue; No digest content identified]

#### **Clinical Pharmacology & Therapeutics**

Volume 114, Issue 4 Pages: 723-932 October 2023 <u>https://ascpt.onlinelibrary.wiley.com/toc/15326535/current</u> [Reviewed earlier]

#### **Clinical Therapeutics**

September 2023 Volume 45 Issue 9 p807-924

http://www.clinicaltherapeutics.com/current [Reviewed earlier]

#### **Clinical Trials**

Volume 20 Issue 5, October 2023 <u>https://journals.sagepub.com/toc/ctja/20/5</u> [Reviewed earlier]

# **Conflict and Health**

http://www.conflictandhealth.com/ [Accessed 21 Oct 2023] [No new digest content identified]

# **Contemporary Clinical Trials**

Volume 133 October 2023 <u>https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/133/suppl/C</u> *Research article Abstract only* <u>Developing and testing a COVID-19 vaccination acceptance intervention: A pragmatic</u> <u>trial comparing vaccine acceptance intervention vs usual care – Rationale, methods, and</u> <u>implementation</u> Jeffrey M. Pyne, Karen H. Seal, Jennifer K. Manuel, Beth DeBonne, ..., A. Rani Elwy

Jeffrey M. Pyne, Karen H. Seal, Jennifer K. Manuel, Beth DeRonne, ... A. Rani Elwy Article 107325

# The CRISPR Journal

Volume 6, Issue 5 / October 2023 <u>https://www.liebertpub.com/toc/crispr/6/5</u> [New issue; No digest content identified]

# **Current Genetic Medicine Reports**

Volume 10, issue 3, September 2022 <u>https://link.springer.com/journal/40142/volumes-and-issues/10-3</u> [Reviewed earlier]

# **Current Medical Research and Opinion**

Volume 39, Issue 10 2023 <u>https://www.tandfonline.com/toc/icmo20/current</u> *Review Article*  **Bioethics of somatic gene therapy: what do we know so far?** Paola Buedo, Alahi Bianchini, Katarzyna Klas & Marcin Waligora Pages: 1355-1365 Published online: 10 Oct 2023

#### **Current Opinion in Infectious Diseases**

October 2023 - Volume 36 - Issue 5 https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx [Reviewed earlier]

#### **Current Protocols in Human Genetics**

https://currentprotocols.onlinelibrary.wiley.com/journal/19348258 [Accessed 21 Oct 2023] [No new digest content identified]

#### **Developing World Bioethics**

Volume 23, Issue 3 Pages: 197-292 September 2023 https://onlinelibrary.wiley.com/toc/14718847/current [Reviewed earlier]

#### **Development in Practice**

Volume 33, Issue 7, 2023 <u>http://www.tandfonline.com/toc/cdip20/current</u> [Reviewed earlier]

#### **Development Policy Review**

Volume 41, Issue 5 September 2023 <u>https://onlinelibrary.wiley.com/toc/14677679/current</u> [Reviewed earlier]

#### **Disaster Medicine and Public Health Preparedness**

Volume 16 - Issue 6 - December 2022 <u>https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue</u> [Reviewed earlier]

#### Disasters

Volume 47, Issue 3 Pages: 543-846 July 2023 https://onlinelibrary.wiley.com/toc/14677717/2023/47/3 [Reviewed earlier]

#### **EMBO Reports**

Volume 24 Issue 10 9 October 2023 https://www.embopress.org/toc/14693178/current [Reviewed earlier]

#### **Emerging Infectious Diseases**

Volume 29, Number 10—October 2023 <u>http://wwwnc.cdc.gov/eid/</u> [Reviewed earlier]

# **Epidemics**

Volume 44 September 2023 <u>https://www.sciencedirect.com/journal/epidemics/vol/44/suppl/C</u> [Reviewed earlier]

# **Epidemiology and Infection**

Volume 151 - 2023 <u>https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue</u> [Reviewed earlier]

#### **Ethics & Human Research**

Volume 45, Issue 5 Pages: 1-47 September–October 2023 <u>https://onlinelibrary.wiley.com/toc/25782363/current</u> *Adaptive clinical trials :: Deprioritizing ongoing clinical trials* [Reviewed earlier]

# **Ethics & International Affairs**

Volume 37 - Issue 2 - Summer 2023 <u>https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue</u> [Reviewed earlier]

# Ethics, Medicine and Public Health

Volume 30 October 2023 <u>https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/30/suppl/C</u> [Reviewed earlier]

#### The European Journal of Public Health

Volume 33, Issue 5, October 2023 <u>https://academic.oup.com/eurpub/issue/33/5</u> [Reviewed earlier]

#### **Expert Review of Vaccines**

Vol 22 (1) 2023 https://www.tandfonline.com/toc/ierv20/current [Reviewed earlier]

#### **Foreign Affairs**

September/October 2023 Volume 102, Number 5 https://www.foreignaffairs.com/issues/2023/102/5 [Reviewed earlier]

#### Forum for Development Studies

Volume 50, 2023 - Issue 3 http://www.tandfonline.com/toc/sfds20/current [Reviewed earlier]

# **Genetics in Medicines**

Volume 25, Issue 10 October 2023 https://www.sciencedirect.com/journal/genetics-in-medicine/vol/25/issue/10 [Reviewed earlier]

# **Genome Medicine**

https://genomemedicine.biomedcentral.com/articles [Accessed 21 Oct 2023] [No new digest content identified]

# **Global Health Action**

Volume 16, Issue 1 (2023) <u>https://www.tandfonline.com/toc/zgha20/current?nav=tocList</u> [Reviewed earlier]

# Global Health: Science and Practice (GHSP)

Vol. 11, No. 4 August 28, 2023 <u>http://www.ghspjournal.org/content/current</u> [Reviewed earlier]

# Global Legal Monitor – Library of Congress/USA

https://www.loc.gov/collections/global-legal-monitor/ [Accessed 21 Oct 2023] [No new digest content identified]

#### **Global Public Health**

Volume 18, Issue 1 (2023) <u>http://www.tandfonline.com/toc/rgph20/current</u> [Reviewed earlier]

# **Globalization and Health**

http://www.globalizationandhealth.com/ [Accessed 21 Oct 2023] [No new digest content identified]

# **Health and Human Rights**

Volume 25, Issue 1, June 2023, <u>https://www.hhrjournal.org/special-section-global-voices-for-global-equity-expanding-right-to-health-frameworks/</u>

*Special Section: Global Voices for Global Justice: Expanding Right to Health Frameworks* ... The papers in this special section work together to move toward a global social medicine for the 22nd century. They envision a global social medicine that confronts and moves beyond the

traditionally colonial, xenophobic, heteronormative, patriarchal, gender-binary-bound, capitalist, and racist histories of the fields of global health and human rights. They seek to instantiate a global social medicine that centers knowledge and experiences from the Global South and works toward social justice and health equity at scale. In this special section, the authors are particularly interested in understanding, challenging, and expanding our perspectives and enactments of the right to health. Unlike neoliberal perspectives on health that often limit their explanatory capacity to how individuals behave in the world, the papers here move beyond the focus on lifestyles and on the phantasmagoria of a sovereign subject with supposedly free agency. Instead, authors work toward critical consciousness that accounts for structural processes—with their inequities and disruptions, as well as their effects on individuals—and how this consciousness can open new horizons for collective transformation and social emancipation in health...

#### Health Economics, Policy and Law

Volume 18 - Special Issue 4 - October 2023 <u>https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue</u> **SPECIAL ISSUE: On the roof top of health policy change** [Reviewed earlier]

#### **Health Policy and Planning**

Volume 38, Issue 8, October 2023 <u>https://academic.oup.com/heapol/issue/38/8</u> [Reviewed earlier]

#### **Health Research Policy and Systems**

http://www.health-policy-systems.com/content [Accessed 21 Oct 2023] [No new digest content identified]

#### **Human Gene Therapy**

Volume 34, Issue 17-18 / September 2023 <u>https://www.liebertpub.com/toc/hum/34/17-18</u> [Reviewed earlier]

#### **Humanitarian Practice Network**

<u>https://odihpn.org/</u> *Featured Publications* [No new digest content identified]

#### Human Vaccines & Immunotherapeutics (formerly Human Vaccines)

Volume 19, Issue 3, 2023 <u>https://www.tandfonline.com/toc/khvi20/19/3?nav=tocList</u> [Reviewed earlier]

#### Immunity

Oct 10, 2023 Volume 56 Issue 10 p2177-2456

https://www.cell.com/immunity/current [Reviewed earlier]

#### **Infectious Agents and Cancer**

http://www.infectagentscancer.com/ [Accessed 21 Oct 2023] [No new digest content identified]

# **Infectious Diseases of Poverty**

http://www.idpjournal.com/content [Accessed 21 Oct 2023] Accelerating into Immunization Agenda 2030 with momentum from China's successful COVID-19 vaccination campaign during dynamic COVID Zero China's immunization programs conducted a unified, tightly coordinated COVID-19 vaccination campaign during the dynamic COVID Zero period that reached well over 90% of the population with vaccines having > 90%... Authors: Lance E. Rodewald Citation: Infectious Diseases of Poverty 2023 12:96 Content type: Commentary Published on: 16 October 2023

#### **International Health**

Volume 15, Issue 5, September 2023 <u>https://academic.oup.com/inthealth/issue/15/5</u> [Reviewed earlier]

#### **International Human Rights Law Review**

Volume 12 (2023): Issue 1 (Jul 2023) https://brill.com/view/journals/hrlr/12/1/hrlr.12.issue-1.xml *Table of Contents* [Reviewed earlier]

#### **International Journal of Community Medicine and Public Health**

Vol. 10 No. 9 (2023): September 2023 https://www.ijcmph.com/index.php/ijcmph/issue/view/104 [Reviewed earlier]

#### **International Journal of Epidemiology**

Volume 52, Issue 4, August 2023 <u>https://academic.oup.com/ije/issue</u> [Reviewed earlier]

#### International Journal of Human Rights in Healthcare

Volume 16 Issue 3 2023 <u>https://www.emerald.com/insight/publication/issn/2056-4902/vol/16/iss/3</u> *Table of contents* 

# JAMA

October 17, 2023, Vol 330, No. 15, Pages 1409-1499 <u>https://jamanetwork.com/journals/jama/currentissue</u> [New issue; No digest content identified]

# JAMA Health Forum

October 2023, Vol 4, No. 10 <u>https://jamanetwork.com/journals/jama-health-forum/issue</u> [Reviewed earlier]

# **JAMA** Pediatrics

October 2023, Vol 177, No. 10, Pages 989-1112 <u>https://jamanetwork.com/journals/jamapediatrics/currentissue</u> [Reviewed earlier]

## JBI Evidence Synthesis

September 2023 - Volume 21 - Issue 9 <u>https://journals.lww.com/jbisrir/Pages/currenttoc.aspx</u> [Reviewed earlier]

## Journal of Adolescent Health

October 2023 Volume 73 Issue 4 p611-796 <u>https://www.jahonline.org/current</u> [Reviewed earlier]

## Journal of Artificial Intelligence Research

Vol. 78 (2023) <u>https://www.jair.org/index.php/jair</u> *Contents* [New issue; No digest content identified]

## **Journal of Community Health**

Volume 48, issue 5, October 2023 https://link.springer.com/journal/10900/volumes-and-issues/48-5 [Reviewed earlier]

## Journal of Current Medical Research and Opinion

...a peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged. June 18, 2023 Vol 6, No 06 (2023) https://www.cmro.in/index.php/jcmro/issue/view/68

## **Journal of Development Economics**

Volume 165 October 2023 <u>https://www.sciencedirect.com/journal/journal-of-development-economics/vol/165/suppl/C</u> [Reviewed earlier]

#### Journal of Empirical Research on Human Research Ethics

Volume 18 Issue 4, October 2023 <u>http://journals.sagepub.com/toc/jre/current</u> *Ethical Issues in Research in Low and Middle-Income Countries* [Reviewed earlier]

#### Journal of Epidemiology & Community Health

September 2023 - Volume 77 - 9 <u>https://jech.bmj.com/content/77/9</u> [Reviewed earlier]

#### Journal of Evidence-Based Medicine

Volume 16, Issue 3 Pages: 259-413 September 2023 <u>https://onlinelibrary.wiley.com/toc/17565391/current</u> [Reviewed earlier]

## **Journal of Global Ethics**

Volume 19, Issue 2 (2023) <u>http://www.tandfonline.com/toc/rjge20/current</u> [Reviewed earlier]

## Journal of Health Care for the Poor and Underserved (JHCPU)

Volume 34, Number 3, August 2023 <u>https://muse.jhu.edu/issue/50808</u> *Table of Contents* [Reviewed earlier]

## Journal of Immigrant and Minority Health

Volume 25, issue 5, October 2023 <u>https://link.springer.com/journal/10903/volumes-and-issues/25-5</u> [Reviewed earlier]

## Journal of Immigrant & Refugee Studies

Volume 21, 2023 \_ Issue 3 <u>https://www.tandfonline.com/toc/wimm20/current</u> [Reviewed earlier]

#### **Journal of Infectious Diseases**

Volume 228, Issue 5, 1 September 2023 <u>https://academic.oup.com/jid/issue/228/5</u> [Reviewed earlier]

#### **Journal of International Development**

Volume 35, Issue 7 Pages: 1549-2249 October 2023 <u>https://onlinelibrary.wiley.com/toc/10991328/current</u> [New issue; No digest content identified]

#### **Journal of Medical Ethics**

October 2023 - Volume 49 - 10 <u>http://jme.bmj.com/content/current</u> [Reviewed earlier]

#### Journal of Patient-Centered Research and Reviews

Volume 10, Issue 3 (2023) <u>https://institutionalrepository.aah.org/jpcrr/</u> [New issue; No digest content identified]

#### The Journal of Pediatrics

Volume 261, October 2023 <u>https://www.sciencedirect.com/journal/the-journal-of-pediatrics/vol/261/suppl/C</u> [Reviewed earlier]

#### **Journal of Pharmaceutical Policy and Practice**

https://joppp.biomedcentral.com/ [Accessed 21 Oct 2023] [No new digest content identified]

#### **Journal of Public Health Management & Practice**

September/October 2023 - Volume 29 - Issue 5 <u>https://journals.lww.com/jphmp/pages/currenttoc.aspx</u> [Reviewed earlier]

#### Journal of Public Health Policy

Volume 44, issue 3, September 2023 <u>https://link.springer.com/journal/41271/volumes-and-issues/44-3</u> [Reviewed earlier]

#### Journal of the Royal Society – Interface

October 2023 Volume 20 Issue 207 https://royalsocietypublishing.org/toc/rsif/current [No new digest content identified]

## **Journal of Travel Medicine**

Volume 30, Issue 5, July 2023 <u>https://academic.oup.com/jtm/issue</u> [Reviewed earlier]

## **Journal of Virology**

Volume 97 Number 9 September 2023 <u>http://jvi.asm.org/content/current</u> [Reviewed earlier]

#### The Lancet

Oct 21, 2023 Volume 402 Number 10411 p1393-1498, e12 https://www.thelancet.com/journals/lancet/issue/current *Review* 

#### Scientific advances and the end of tuberculosis: a report from the Lancet Commission on Tuberculosis

Michael Reid, get al.

The 2019 Lancet Commission on Tuberculosis laid out an optimistic vision for how to build a tuberculosis-free world through smart investments based on sound science and shared responsibility. <u>1</u> Since then, several major strides have been made towards ending tuberculosis, including substantive improvements in treatment outcomes for people with drug-resistant disease. <u>2</u>

, <u>3</u> Although COVID-19 has undermined global progress, many African countries have sustained declines in tuberculosis mortality rates. With excellent short-course preventive regimens and several late-stage vaccine candidates, tuberculosis prevention is also on the cusp of a revolution. Still, much more can be done to fully implement the Commission's recommendations (<u>panel 1</u>) and realise the ambitious targets set out at the UN High-Level Meeting (HLM) on tuberculosis in 2018. In the 5 years since the HLM, more than 7 million people have died of tuberculosis; their deaths are a profound tragedy and a reminder of the urgency of accelerating momentum.

## The Lancet Child & Adolescent Health

Nov 2023 Volume 7 Number 11 p747-814, e18-e20 https://www.thelancet.com/journals/lanchi/issue/current *Editorial* 

## Child poverty in 2023: inequity in times of crises

The Lancet Child & Adolescent Health

... While lifting children out of poverty remains a key priority, it is also important to prevent vulnerable households from tipping, or sliding back, into poverty. WHO estimates that out-of-pocket spending on health pushes 100 million people into extreme poverty each year, and universal health coverage is therefore an essential component of reducing child poverty. Ensuring access to high-quality health care, early child development programmes, education, and social protection is foundational to breaking the insidious cycle of poverty. Having witnessed how severely a global pandemic can compound vulnerability to poverty, it is necessary that these systems and programmes are resilient to severe shocks in the future.

Worldwide, paediatricians have a crucial role in supporting children and families in coping with the health burden of poverty and referring them to relevant services. But individual-level efforts are

uphill battles when surrounding systems are inherently inequitable. When, for example, a fully vaccinated, breastfeeding child is malnourished because the family does not have enough food or secure housing, there is little that individual paediatricians can do. It is incumbant on all sectors of society to unify towards liberating resources for households and supporting children's social mobility out of poverty. This starts by governments placing children at the heart of all policies and investing in the programmes that will see child poverty, in all its dimensions, tackled.

#### Review

#### The evolving treatment landscape for children with sickle cell disease

Seethal A Jacob, Ravi Talati, Julie Kanter

#### Summary

Sickle cell disease is the most common inherited pathological haemoglobinopathy. Over the past 30 years, disease-related morbidity and mortality have improved in high-income countries due to advances in preventive care and treatments. Established disease-modifying therapies, such as hydroxyurea (hydrocarbamide), are continuing to have an important role in the treatment of sickle cell disease, and newer agents also show promise. In the past 5 years, the US Food and Drug Administration approved three additional sickle cell disease-modifying medications, and new gene therapies have been developed as an alternative curative treatment to haematopoietic stem-cell transplantation. In this Review, we discuss the current treatment landscape for paediatric sickle cell disease and emerging innovations in care. We also review the need for close, long-term management for children receiving newer therapies and the importance of ongoing investment in people with sickle cell disease in low-income and middle-income countries.

#### Lancet Digital Health

Oct 2023 Volume 5 Number 10 e632-e748 <u>https://www.thelancet.com/journals/landig/issue/current</u> *Review* 

#### FAIR, ethical, and coordinated data sharing for COVID-19 response: a scoping review and cross-sectional survey of COVID-19 data sharing platforms and registries

Lauren Maxwell, et al.

Summary

Data sharing is central to the rapid translation of research into advances in clinical medicine and public health practice. In the context of COVID-19, there has been a rush to share data marked by an explosion of population-specific and discipline-specific resources for collecting, curating, and disseminating participant-level data. We conducted a scoping review and cross-sectional survey to identify and describe COVID-19-related platforms and registries that harmonise and share participant-level clinical, omics (eg, genomic and metabolomic data), imaging data, and metadata. We assess how these initiatives map to the best practices for the ethical and equitable management of data and the findable, accessible, interoperable, and reusable (FAIR) principles for data resources. We review gaps and redundancies in COVID-19 data-sharing efforts and provide recommendations to build on existing synergies that align with frameworks for effective and equitable data reuse. We identified 44 COVID-19-related registries and 20 platforms from the scoping review. Data-sharing resources were concentrated in high-income countries and siloed by comorbidity, body system, and data type. Resources for harmonising and sharing clinical data were less likely to implement FAIR principles than those sharing omics or imaging data. Our findings are that more data sharing does not equate to better data sharing, and the semantic and technical interoperability of platforms and registries harmonising and sharing COVID-19-related participantlevel data needs to improve to facilitate the global collaboration required to address the COVID-19 crisis.

Health Policy

# Mapping and evaluating national data flows: transparency, privacy, and guiding infrastructural transformation

Joe Zhang, et al.

#### Summary

The importance of big health data is recognised worldwide. Most UK National Health Service (NHS) care interactions are recorded in electronic health records, resulting in an unmatched potential for population-level datasets. However, policy reviews have highlighted challenges from a complex data-sharing landscape relating to transparency, privacy, and analysis capabilities. In response, we used public information sources to map all electronic patient data flows across England, from providers to more than 460 subsequent academic, commercial, and public data consumers. Although NHS data support a global research ecosystem, we found that multistage data flow chains limit transparency and risk public trust, most data interactions do not fulfil recommended best practices for safe data access, and existing infrastructure produces aggregation of duplicate data assets, thus limiting diversity of data and added value to end users. We provide recommendations to support data infrastructure transformation and have produced a website (<u>https://DataInsights.uk</u>) to promote transparency and showcase NHS data assets.

#### Lancet Global Health

Nov 2023 Volume 11 Number 11 e1667-e1826 https://www.thelancet.com/journals/langlo/issue/current Articles

Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in infants: a phase 2, randomised, double-blind, active-controlled trial in Guinea and Sierra Leone

Edward Man-Lik Choi, et al. for the EBOVAC-3/EBL2005 Study Team

#### Review

The effect and control of malaria in pregnancy and lactating women in the Asia-Pacific region

Holger W Unger, et al.

#### Health Policy

<u>Clinical and regulatory development strategies for Shigella vaccines intended for</u> <u>children younger than 5 years in low-income and middle-income countries</u> Birgitte K Giersing, et al.

#### **Lancet Infectious Diseases**

Oct 2023 Volume 23 Number 10 p1095-1206, e390-e454 <u>https://www.thelancet.com/journals/laninf/issue/current</u> *Editorial* <u>Can we control dengue?</u> The Lancet Infectious Diseases

#### Articles

Safety of monovalent and bivalent BNT162b2 mRNA COVID-19 vaccine boosters in atrisk populations in Israel: a large-scale, retrospective, self-controlled case series study Dan Yamin, et al. Safety, immunogenicity and protection of heterologous boost with an aerosolised Ad5nCoV after two-dose inactivated COVID-19 vaccines in adults: a multicentre, open-label phase 3 trial

Jing-Xin Li, et al. for the Six-Province COVID-19 Vaccine Study Group

Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in adults primed with a Japanese encephalitis virus or yellow fever virus vaccine in the USA: a phase 1, randomised, double-blind, placebo-controlled clinical trial Michael A Koren, et al.

Safety and immunogenicity of a novel multivalent OspA-based vaccine candidate against Lyme borreliosis: a randomised, phase 1 study in healthy adults Nicole Bézay, et al.

#### **Lancet Public Health**

Oct 2023 Volume 8 Number 10 e743-e826 <u>https://www.thelancet.com/journals/lanpub/issue/current</u> *Articles* <u>Potential population-level effectiveness of one-dose HPV vaccination in low-income and</u> <u>middle-income countries: a mathematical modelling analysis</u> Élodie Bénard, et al.

#### Lancet Respiratory Medicine

Oct 2023 Volume 11 Number 10 p851-944, e84-e88 <u>https://www.thelancet.com/journals/lanres/issue/current</u> [New issue; No digest content identified]

#### **Maternal and Child Health Journal**

Volume 27, issue 9, September 2023 <u>https://link.springer.com/journal/10995/volumes-and-issues/27-9</u> [Reviewed earlier]

#### Medical Decision Making (MDM)

Volume 43 Issue 6, August 2023 <u>http://mdm.sagepub.com/content/current</u> [Reviewed earlier]

#### The Milbank Quarterly

A Multidisciplinary Journal of Population Health and Health Policy Volume 101, Issue 3 Pages: 637-998 September 2023 <u>https://onlinelibrary.wiley.com/toc/14680009/current</u> [Reviewed earlier]

#### **Molecular Therapy**

Oct 04, 2023 Volume 31 Issue 10 p2813-3104 https://www.cell.com/molecular-therapy/current

## Nature

Volume 622 Issue 7983, 19 October 2023 <u>https://www.nature.com/nature/volumes/622/issues/7983</u> *Editorial* 17 Oct 2023 <u>How to share data — not just equally, but equitably</u>

Just as with many natural resources, wealthy countries have been extracting scientific data from poorer nations for centuries. Researchers are changing that.

## **Nature Biotechnology**

Volume 41 Issue 10, October 2023 https://www.nature.com/nbt/volumes/41/issues/10 [Reviewed earlier]

## **Nature Communications**

https://www.nature.com/subjects/health-sciences/ncomms (Accessed21 Oct 2023) [No new digest content identified]

# **Nature Genetics**

Volume 55 Issue 10, October 2023 <u>https://www.nature.com/ng/volumes/55/issues/10</u> [Reviewed earlier]

# Nature Human Behaviour

Volume 7 Issue 9, September 2023 <u>https://www.nature.com/nathumbehav/volumes/7/issues/9</u> [Reviewed earlier]

## **Nature Medicine**

Volume 29 Issue 10, October 2023 <u>https://www.nature.com/nm/volumes/29/issues/10</u> [New issue; No digest content identified]

# **Nature Reviews Drug Discovery**

Volume 22 Issue 10, October 2023 <u>https://www.nature.com/nrd/volumes/22/issues/10</u> [New issue; No digest content identified]

## **Nature Reviews Genetics**

Volume 24 Issue 10, October 2023 <u>https://www.nature.com/nrg/volumes/24/issues/10</u> [Reviewed earlier]

## **Nature Reviews Immunology**

Volume 23 Issue 10, October 2023 <u>https://www.nature.com/nri/volumes/23/issues/10</u> [New issue; No digest content identified]

#### **New England Journal of Medicine**

October 19, 2023 Vol. 389 No. 16 <u>https://www.nejm.org/toc/nejm/medical-journal</u> [New issue; No digest content identified]

## njp Vaccines

https://www.nature.com/npjvaccines/ [Accessed 21 Oct 2023] [No new digest content identified]

#### **Pediatrics**

Volume 152, Issue 4 October 2023 <u>https://publications.aap.org/pediatrics/issue/152/4</u> [Reviewed earlier]

#### **PharmacoEconomics**

Volume 41, issue 10, October 2023 <u>https://link.springer.com/journal/40273/volumes-and-issues/41-10</u> [Reviewed earlier]

## **PLoS Biology**

https://journals.plos.org/plosbiology/ (Accessed 21 Oct 2023)

**Open Science 2.0: Towards a truly collaborative research ecosystem** 

Robert T. Thibault, Olavo B. Amaral, Felipe Argolo, Anita E. Bandrowski, Alexandra R, Davidson, Natascha I. Drude

*Essay* | published 19 Oct 2023 PLOS Biology https://doi.org/10.1371/journal.pbio.3002362

Abstract

Conversations about open science have reached the mainstream, yet many open science practices such as data sharing remain uncommon. Our efforts towards openness therefore need to increase in scale and aim for a more ambitious target. We need an ecosystem not only where research outputs are openly shared but also in which transparency permeates the research process from the start and lends itself to more rigorous and collaborative research. To support this vision, this Essay provides an overview of a selection of open science initiatives from the past 2 decades, focusing on methods transparency, scholarly communication, team science, and research culture, and speculates about what the future of open science could look like. It then draws on these examples to provide recommendations for how funders, institutions, journals, regulators, and other stakeholders can create an environment that is ripe for improvement.

## **PLoS Genetics**

https://journals.plos.org/plosgenetics/ (Accessed 21 Oct 2023) [No new digest content identified]

# **PLoS Global Public Health**

https://journals.plos.org/globalpublichealth/search?sortOrder=DATE\_NEWEST\_FIRST&filterStartDate =2021-10-01&filterJournals=PLOSGlobalPublicHealth&q=&resultsPerPage=60 (Accessed 21 Oct 2023) *Review* Global regulatory reforms to promote equitable vaccine access in the next pandemic Richard Mahoney, Peter J. Hotez, Maria Elena Bottazzi | published 18 Oct 2023 PLOS Global Public Health https://doi.org/10.1371/journal.pgph.0002482

#### Abstract

There is broad consensus that the global response to the Covid-19 pandemic was inadequate, leading to unacceptable levels of avoidable morbidity and mortality. Three strategic missteps led to the lack of equitable vaccine access: The heavy reliance on commercial vaccine manufacturers in high-income countries (HICs) versus low- and middle-income countries (LMICs); the emergence of vaccine nationalism restricting and delaying the supply of vaccines to LMICs; and an inadequate support or recognition for LMIC national regulatory authorities. To avoid these inequities in a future pandemic, we focus on three successful vaccine development and technology transfer case studiesthe Hepatitis B vaccine produced in South Korea in the 1980s; the Meningitis A vaccine for Africa led by Program for Appropriate Technologies in Health (PATH) and the World Health Organization (WHO) in the 2000s; and a recombinant SARS CoV-2 protein-based vaccine technology from the Texas Children's Hospital transferred to India and to Indonesia. In addition to expanding support for academic or non-profit product development partnerships, our analysis finds that an essential step is the strengthening of selected LMIC regulatory systems to become Stringent Regulatory Authorities (SRAs), together with a re-prioritization of the WHO Pregualification (PQ) system to ensure early vaccine availability in LMICs especially during pandemics. Advancing LMIC National Regulatory Authorities (NRAs) to Stringent Regulatory Authorities (SRAs) status will require substantial resources, but the benefits for future pandemic control and for health in LMIC would be immense. We call on the WHO, United Nation (UN) agencies and SRAs, to collaborate and implement a comprehensive roadmap to support LMIC regulators to achieve stringent status by 2030.

## **PLoS Medicine**

http://www.plosmedicine.org/ (Accessed 21 Oct 2023) [No new digest content identified]

# **PLoS Neglected Tropical Diseases**

<u>http://www.plosntds.org/</u> (Accessed 21 Oct 2023) [No new digest content identified]

# PLoS One

http://www.plosone.org/

[Accessed 21 Oct 2023] Post-epidemic health system recovery: A comparative case study analysis of routine immunization programs in the Republics of Haiti and Liberia Saniana 1 Pavi, Christina M. Potter, Ligia Paina, Maria W. Morritt

Sanjana J. Ravi, Christina M. Potter, Ligia Paina, Maria W. Merritt Research Article | published 17 Oct 2023 PLOS ONE <u>https://doi.org/10.1371/journal.pone.0292793</u>

#### Poor reporting quality of randomized controlled trials comparing treatments of COVID-19–A retrospective cross-sectional study on the first year of publications

Linda Grüßer, Charlotte Eißing, Ana Kowark, András P. Keszei, Julia Wallqvist, Rolf Rossaint, Sebastian Ziemann Research Article | published 16 Oct 2023 PLOS ONE https://doi.org/10.1371/journal.pone.0292860

# **PLoS Pathogens**

http://journals.plos.org/plospathogens/ [Accessed 21 Oct 2023] [No new digest content identified]

# **PNAS - Proceedings of the National Academy of Sciences of the United States**

October 17, 2023 | vol. 120 | no. 42 <u>https://www.pnas.org/toc/pnas/120/42</u> [New issue; No digest content identified]

## **PNAS Nexus**

Volume 2, Issue 9, September 2023 <u>https://academic.oup.com/pnasnexus/issue/2/9</u> [Reviewed earlier]

# **Prehospital & Disaster Medicine**

Volume 38 - Issue 5 - October 2023 <u>https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue</u> [Reviewed earlier]

# **Preventive Medicine**

Volume 174 September 2023 <u>https://www.sciencedirect.com/journal/preventive-medicine/vol/174/suppl/C</u> [Reviewed earlier]

# Proceedings of the Royal Society B

25 October 2023 Volume 290 Issue 2009 https://royalsocietypublishing.org/toc/rspb/current [New issue; No digest content identified]

## **Public Health**

Volume 223 Pages e1-e16, 1-256 (October 2023) <u>https://www.sciencedirect.com/journal/public-health/vol/223/suppl/C</u> [Reviewed earlier]

#### **Public Health Ethics**

Volume 16, Issue 2, July 2023 <u>http://phe.oxfordjournals.org/content/current</u> [Reviewed earlier]

#### **Public Health Genomics**

2023, Vol. 26, No. 1 <u>https://karger.com/phg/issue/26/1</u> [Reviewed earlier]

#### **Public Health Reports**

Volume 138 Issue 5, September/October 2023 https://journals.sagepub.com/toc/phrg/138/5 [Reviewed earlier]

#### **Qualitative Health Research**

Volume 33 Issue 12, October 2023 https://journals.sagepub.com/toc/QHR/current [Reviewed earlier]

#### **Research Ethics**

Volume 19 Issue 4, October 2023 <u>http://journals.sagepub.com/toc/reab/current</u> [Reviewed earlier]

#### **Reproductive Health**

http://www.reproductive-health-journal.com/content [Accessed 21 Oct 2023] [No new digest content identified]

# Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)

https://www.paho.org/journal/en [No new digest content identified]

#### **Risk Analysis**

Volume 43, Issue 10 Pages: 1917-2146 October 2023 <u>https://onlinelibrary.wiley.com/toc/15396924/current</u> [Reviewed earlier]

#### **Risk Management and Healthcare Policy**

https://www.dovepress.com/risk-management-and-healthcare-policy-archive56

[Accessed 21 Oct 2023] [Reviewed earlier]

#### Science

Volume 382| Issue 6668| 20 Oct 2023 https://www.science.org/toc/science/current *Editorial* **Safeguard the world's worst pathogens** BY Piers Millett 19 Oct 2023: 243

## **Science and Engineering Ethics**

Volume 29, issue 5, October 2023 <u>https://link.springer.com/journal/11948/volumes-and-issues/29-5</u> [Reviewed earlier]

## **Science Translational Medicine**

Volume 15| Issue 718| 18 Oct 2023 https://www.science.org/toc/stm/current

Special issue: Zoonotic diseases

Editorial

What keeps me up at night

BY Anthony S. Fauci

18 Oct 2023

The lessons of COVID-19 must be heeded if the world is to be prepared for the next emergent pathogen with pandemic potential.

#### Viewpoints

Drug discovery in Africa tackles zoonotic and related infections

BY Christabel N. Hikaambo, et al.

18 Oct 2023

African drug discovery scientists are making headway in addressing the burden of zoonotic and related infections on their continent.

#### Many potential pathways to future pandemic influenza

BY David M. Morens, Jaekeun Park, Jeffery K. Taubenberger 18 Oct 2023

Influenza pandemics have emerged for centuries but still cannot be accurately predicted.

# Zoonotic mosquito-borne arboviruses: Spillover, spillback, and realistic mitigation strategies

BY Rafael K. Campos, Shannan L. Rossi, Robert B. Tesh, Scott C. Weaver 18 Oct 2023

Mosquito-borne viruses increasingly threaten human health, requiring enhanced surveillance, prevention, and treatment strategies to prevent outbreaks.

### A ticking time bomb hidden in plain sight

BY Sukanya Narasimhan, et al.

18 Oct 2023

It is time for a One Health approach to address the rising threat of tick-borne diseases.

## Wastewater surveillance facilitates climate change-resilient pathogen monitoring

BY Megan B. Diamond, et al. 18 Oct 2023

Wastewater surveillance data can inform how climate change impacts pathogen dynamics and guide stronger public health intervention strategies

## **Scientific Reports**

https://www.nature.com/srep/articles?type=article [Accessed 21 Oct 2023] [No new digest content identified]

# **Social Science & Medicine**

Volume 332 September 2023 <u>https://www.sciencedirect.com/journal/social-science-and-medicine/vol/332/suppl/C</u> [Reviewed earlier]

# **Systematic Reviews**

https://systematicreviewsjournal.biomedcentral.com/articles [Accessed 21 Oct 2023] [No new digest content identified]

## **Theoretical Medicine and Bioethics**

Volume 44, issue 5, October 2023 https://link.springer.com/journal/11017/volumes-and-issues/44-5 https://royalsocietypublishing.org/toc/rspb/current [New issue; No digest content identified]

# **Travel Medicine and Infectious Diseases**

Volume 55 September–October 2023 <u>https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/55/suppl/C</u> [Reviewed earlier]

## **Tropical Medicine & International Health**

Volume 28, Issue 10 Pages: i-iv, 797-838 October 2023 https://onlinelibrary.wiley.com/toc/13653156/current [Reviewed earlier]

# Vaccine

Volume 41, Issue 45 Pages 6625-6774 (26 October 2023) https://www.sciencedirect.com/journal/vaccine/vol/41/issue/45 Research article Abstract only

<u>"The problem is not lack of information": A qualitative study of parents and school</u> <u>nurses' perceptions of barriers and potential solutions for HPV vaccination in schools</u> Maude Dionne, Chantal Sauvageau, Marilou Kiely, Mika Rathwell, ... Ève Dubé Pages 6654-6660

Research article Open access

Exploring factors that influence vaccination uptake for children with refugee backgrounds: An interpretive description study of primary healthcare providers' perspectives Larisa Cavit, Nadia A. Charania

Pages 6690-6699

Research article Abstract only

How to increase and maintain high immunization coverage: Vaccination Demand Resilience (VDR) framework

Sachiko Ozawa, Holly B. Schuh, Tomoka Nakamura, Tatenda T. Yemeke, ... Noni E. MacDonald Pages 6710-6718

Article(s) from the Special Issue on "Latest developments in vaccine research: The 16th Vaccine Congress"; Edited by Dior Beerens and Gregory Poland Editorial Latest developments in vaccine research: Selected papers from the 16th annual vaccine congress

Dior Beerens, Gregory A. Poland Page 6761

Vaccines https://www.mdpi.com/journal/vaccines [Accessed 21 Oct 2023] Latest Articles [Selected] Open Access Article Stakeholders' Understanding of European Medicine Agency's COVID-19 Vaccine Information Materials in EU and Regional Contexts by Indiana Castro, et al. Vaccines 2023, 11(10), 1616; https://doi.org/10.3390/vaccines11101616 - 19 Oct 2023

Abstract The COVID-19 pandemic posed challenges to communicating accurate information about vaccines because of the spread of misinformation. The European Medicines Agency (EMA) tried to reassure

the public by communicating early on about the development and approval of COVID-19 vaccines. The EMA surveyed patients/consumers...

## Value in Health

October 2023 Volume 26 Issue 10 p1435-1580 https://www.valueinhealthjournal.com/current [Reviewed earlier]

::::::

Contents [click to move among sections] :: <u>Milestones, Perspectives</u> :: <u>WHO</u> :: <u>Organization Announcements</u> :: <u>Journal Watch</u>

:: <u>Pre-Print Servers</u>

## **Pre-Print Servers**

#### **Gates Open Research**

https://gatesopenresearch.org/browse/articles [Accessed 21 Oct 2023] Selected Research No new digest content identified.

#### medRxiv

https://www.medrxiv.org/content/about-medrxiv [Accessed 21 Oct 2023] [Filter: All articles] Selected Research COVID-19 cases associated with testing policies in 34 highly democratic countries, 2020-2022

Leon S. Robertson medRxiv 2023.10.19.23297270; doi: https://doi.org/10.1101/2023.10.19.23297270 *Abstract* 

COVID-19 testing policies varied in time from testing only the symptomatic, testing the symptomatic and persons at higher risk of severe disease, on-demand testing for people who wanted one, and two periods of government-imposed mass testing in Slovakia. Using Poisson regression, this study examines the associations of COVID-19 cases during the times that the noted policies were in effect in 34 countries rated highest on democracy scores. Statistically corrected for other risk factors, increases in negative tests were associated with subsequent surges in cases when on-demand testing was promoted, particularly when coupled with poor contact tracing. Mass testing in Slovakia was associated with reduced spread of the virus for short periods but was deemed unsustainable. The data support the hypothesis that on-demand testing resulted in the unanticipated consequence of increased travel and increased exposure of travelers to the virus.

#### <u>Real-world data: A systematic literature review on the barriers, challenges, and</u> <u>opportunities associated with their inclusion in the health technology assessment</u> <u>process</u>

Konstantinos Zisis, Elpida Pavi, Mary Geitona, Kostas Athanasakis medRxiv 2023.10.18.23297151; doi: https://doi.org/10.1101/2023.10.18.23297151

#### **OSF Pre-prints**

<u>https://osf.io/preprints/discover?provider=OSF&subject=bepress%7 CLife%20Sciences</u> [Provider Filter: OSF Pre-prints Subject filters: Arts & Humanities; Education, Life Sciences; Medicine and Health Sciences; Social and Behavioral Sciences] **We observe increasing levels of "posting pollution" by individuals, sometimes posting 10+ items of no value. We will resume selective monitoring beginning in September.** 

#### Wellcome Open Research

https://wellcomeopenresearch.org/browse/articles [Accessed 21 Oct 2023] Selected Research No new digest content identified.

\* \* \* \*

# <u>Think Tanks</u>

**Brookings** [to 21 Oct 2023] http://www.brookings.edu/ *Research No new digest content identified.* 

#### Center for Global Development [to 21 Oct 2023]

<u>https://www.cgdev.org/</u> *All Research [Selected] No new digest content identified.* 

Chatham House [to 21 Oct 2023] https://www.chathamhouse.org/ Selected Analysis, Comment, Events No new digest content identified.

## Council on Foreign Relations [to 21 Oct 2023]

https://www.cfr.org/media/news-releases New Releases [Selected] No new digest content identified.

CSIS [to 21 Oct 2023] https://www.csis.org/ Reports [Selected] Centering PEPFAR in U.S. Global Health Security Strategies

The CSIS Working Group on Reinvigorating U.S. Leadership on HIV/AIDS offers recommendations for advancing progress on reaching the goal of eliminating HIV as a global public health threat by 2030 while maximizing the contributions to pandemic preparedness and response. *Brief* by Katherine E. Bliss — October 19, 2023

**Kaiser Family Foundation** [to21 Oct 2023] https://www.kff.org/search/?post\_type=press-release Newsroom No new digest content identified.

#### McKinsey Global Institute [to 21 Oct 2023]

https://www.mckinsey.com/mgi/overview Latest Research No new digest content identified.

# ODI [Overseas Development Institute] [to 21 Oct 2023]

https://odi.org/en/publications/ Publications [Selected] No new digest content identified.

## Pew Research Center [to 21 Oct 2023]

https://www.pewresearch.org/ Latest Publications [Selected] No new digest content identified.

Rand [to 21 Oct 2023] https://www.rand.org/pubs.html Published Research [Selected] Report

## The Operational Risks of AI in Large-Scale Biological Attacks: A Red-Team Approach

In this report, the authors address the emerging issue of identifying and mitigating the risks posed by the misuse of artificial intelligence—specifically, large language models—in the context of biological attacks and present preliminary findings. Oct 16, 2023

Christopher A. Mouton, Caleb Lucas, Ella Guest

Urban Institute [to 21 Oct 2023] https://www.urban.org/publications New Research Publications - Selected

Brief Research Within versus Outside Existing Systems: Framing and Studying the Effects of Structural Racism October 19, 2023

## World Economic Forum [to 21 Oct 2023]

https://agenda.weforum.org/press/ Media

**Global Experts Call for Interdisciplinary Approaches to Improve Decision-Making** 18.10.2023

:: A diverse network of more than 450 global experts at the World Economic Forum's Annual Meeting of the Global Future Councils 2023 highlighted the value of interdisciplinary and multistakeholder solutions to economic, technological, societal and environmental challenges in the face of geopolitical and economic uncertainty.

:: The cross-cutting programme in Dubai addressed harnessing artificial intelligence, accelerating the green transition, reviving productivity, addressing antimicrobial resistance and stabilizing trade.

:: 30 councils developed proposals for collaboration that can create transformative change in the next three years in each of their topic areas.

:::::: :::::::

## **Public Consultations/Call for Papers**

## <u>Call for Contributions - OHCHR analytical study on key challenges in ensuring access to</u> <u>medicines, vaccines and other health products (HRC resolution 50/13)</u>

Office of the High Commissioner for Human Rights | Call for input | Treaty bodies

## Deadline: 30 November 2023

Purpose:

To inform the OHCHR analytical study on key challenges in ensuring access to medicines, vaccines and other health products (HRC resolution 50/13)

#### Background:

Vaccine equity and access to medicines is a fundamental component of the full realization of the right to health. Vaccines, medicines and other health products must not only be produced and made available - they must also be accessible to all persons. Yet, access to vaccines, medicines and other health products remains disturbingly uneven in many places.

Council resolution 50/13 requests the Office of the High Commissioner for Human Rights (OHCHR) to prepare an analytical study on key challenges in ensuring access to medicines, vaccines and other health products to be presented to the Human Rights Council at the fifty-sixth session in June 2024. In order to collect inputs for this forthcoming report, OHCHR has published a short questionnaire available in English, Français and Español.

\* \* \* \* \* \* \*

*Vaccines and Global Health: The Week in Review* is a service of the Center for Vaccine Ethics and Policy (<u>CVEP</u>) / GE2P2 Global Foundation, which is solely responsible for its content.

#### .....

Copyright GE2P2 Global Foundation 2023. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <u>http://creativecommons.org/licenses/by/4.0/</u> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

#### :::::::

CVEP is a program of the <u>GE2P2 Global Foundation</u> whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in

health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the <u>Bill & Melinda Gates Foundation</u>; the <u>Bill & Melinda Gates</u> <u>Medical Research Institute</u>, and industry resource members Janssen/J&J, Pfizer, Sanofi US, and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

*	*	*	*
*	*	*	*